1. Allergan buys back $2B in stock same day CFO announces retirement
Allergan’s board of directors authorized a $2 billion buyback of the drugmaker’s stock.
2. MD Anderson, Pfizer to collaborate on immunotherapy research
The University of Texas MD Anderson Cancer Center in Houston launched a clinical collaboration with Pfizer to study the use of immuno-oncology drugs to treat various solid tumors and blood cancers.
3. Hurricane Maria stalls shipments of Baxter’s IV products to US hospitals: 4 things to know
Baxter International notified customers of shipment delays for two drugs — dextrose and sodium chloride — following Hurricane Maria.
4. AmerisourceBergen fined $260M over cancer drug packaging: 4 things to know
AmerisourceBergen pleaded guilty to a federal misdemeanor charge for selling prefilled syringes of oncology drugs packaged in a facility not registered with the Food and Drug Administration.
5. Amgen to launch Humira biosimilar in 2023 following Abbvie settlement
Amgen settled a patent lawsuit with Abbvie over its biosimilar version of Abbvie’s best-selling arthritis drug Humira.
More articles on supply chain:
US Army delivers 3-day fuel supply to Puerto Rican children’s hospital
Why pharmaceutical products in the US don’t include braille labeling
Rite Aid names former Walgreens executive as president, COO
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.